St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

Mar 12 2010

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

“We offer a full range of products and technologies from across the company designed to decrease hospitalizations, improve patient quality of life and reduce healthcare costs.”

“St. Jude Medical is pleased to showcase our latest cardiac care solutions, from technologies that help to better connect patients to physicians, to devices proven to improve patient outcomes,” said Frank Callaghan, president of the St. Jude Medical Cardiovascular Division. “We offer a full range of products and technologies from across the company designed to decrease hospitalizations, improve patient quality of life and reduce healthcare costs.”

Products and technologies will be on display at St. Jude Medical booth 718 during the American College of Cardiology (ACC) Conference at the Georgia World Congress Center on Sunday, March 14, 9 a.m. - 4:30 p.m., Monday, March 15, 9 a.m. - 4:30 p.m. and Tuesday, March 16, 9 a.m. - 1 p.m., including:

Cardiovascular Division

• Engage™ Family of Introducers: This new product line was designed to provide physicians with reliable access and set the stage for closure using the Angio-Seal™ device. The Engage™ Introducer is used for femoral access, in which physicians access the patient’s heart through the femoral vein or artery located near the groin. The Engage TR™ Introducer portfolio expands the company’s product offering to include introducers used for radial access, in which physicians access the patient’s heart through the radial artery in the arm. The Engage Introducers have received FDA clearance and CE Mark approval.
• PressureWire™ technology: The landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) study compared FFR-guided treatment using a St. Jude Medical PressureWire to treatment using standard angiography alone, and found both superior clinical outcomes and reduced healthcare costs in patients whose treatment was based on FFR. The next generation of PressureWire™ Certus is the only guidewire on the market to offer in one wire the combined measurement of pressure and temperature which enables calculations of FFR, Coronary Flow Reserve (CFR) and an Index of Microcirculatory Resistance (IMR). The PressureWire™ Aeris is a first-of-its-kind wireless FFR measuring system requiring no additional equipment or cabling and gives physicians instant access to patient data; it can be used with multiple recording systems including the GE Mac-Lab® Hemodynamic Recording System, Mennen Horizon XVu and the McKesson Horizon Cardiology Hemo™ solution. Both products have FDA clearance and CE Mark approval.
• Other Interventional Cardiology and Cardiac Surgery Products on Display: Epic™ Stented Tissue Valves with Linx AC Technology, Biocor™ Stented Tissue Valves, Attune™ Flexible Adjustable Annuloplasty Ring, and Regent™ Mechanical Heart Valve.

Atrial Fibrillation Division

• EnSite Velocity™ Cardiac Mapping System: The next-generation of the industry-leading EnSite™ System is designed to help physicians more efficiently diagnose and guide therapy to treat abnormal heart rhythms. The EnSite Velocity System creates a three-dimensional (3D) model of the patient’s heart, allowing physicians to visualize a patient’s cardiac chamber in great detail. Physicians can then quickly locate the source of the arrhythmia and formulate a treatment strategy. The new platform is customizable, providing the flexibility to better integrate current and future technology. The EnSite Velocity System has received FDA clearance and CE Mark approval.
• EP-WorkMate™ Recording System: The system is a highly sophisticated, yet simple to use workstation that digitizes cardiac signals for diagnosis by an electrophysiologist, and also serves as the technology platform for the seamless integration of other systems, software and products used in the EP lab. With its unique real-time information sharing capabilities, the EP-Workmate puts nearly everything needed to complete a study right at the EP’s fingertips. The EP-WorkMate system has received FDA clearance and CE Mark approval.
• Other EP Access, Diagnostic and Therapeutic Products on Display: Agilis™ NxT Steerable Introducer, ACross Transseptal System, Reflexion™ HD High Density Mapping Catheter, ViewMate™ II Intracardiac Ultrasound System, Safire™ family of ablation catheters, and Therapy™ Cool Path™ Irrigated Ablation Catheter.

In addition, results from the CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) feasibility study are being presented as a late-breaking trial at ACC on the morning of Monday, March 15. Results from the study, which was sponsored by St. Jude Medical, will reveal updated information about patients enrolled in the pilot phase of the study, which compares catheter ablation to current state-of-the-art medical therapy in patients with atrial fibrillation.

Cardiac Rhythm Management Division

• Accent™ RF and Anthem™ RF Pacemakers: The market’s first devices to simplify patient management – from implant through follow-up – with wireless monitoring, the Accent RF pacemaker and Anthem RF cardiac resynchronization therapy pacemaker (CRT-P) enable physicians to wirelessly program the devices, transmit comprehensive diagnostic data and be alerted to important changes in the device or with the patient’s condition through the Merlin.net™ PCN (Patient Care Network). The Accent RF and Anthem RF pacemakers have received FDA and CE Mark approval.
• Durata™ Defibrillation Lead with SJ4 Connector: The SJ4 connector system features a single connection, rather than three, between the device and the defibrillation lead, and a single set screw (used to tighten and secure the lead to the device). Previous defibrillator lead designs required at least three separate connections and as many as eight set screws. The reduced number of lead connections may also lessen the risk of lead-to-can abrasion, a known complication that can occur in patients who have an implantable device. The SJ4 connector system is used with the Current™ Plus ICD and Promote™ Plus CRT-D, which have both received FDA approval. The Durata Defibrillation Lead with SJ4 Connector has received FDA and CE Mark approval.
• Other CRM Products on display: Zephyr™ pacemaker, SJM Confirm™ Implantable Cardiac Monitor, Microny™ pacemaker, QuickFlex™ lead, QuickFlex™ XL lead, OptiSense™ 1999 Optim™ lead, Tendril™ STS 2088 Optim™ lead, IsoFlex™ Optim® lead, Merlin™ programmer, Merlin.net™ Patient Care System, and Merlin@home™ transmitter.